ATE458006T1 - Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa - Google Patents

Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa

Info

Publication number
ATE458006T1
ATE458006T1 AT03010836T AT03010836T ATE458006T1 AT E458006 T1 ATE458006 T1 AT E458006T1 AT 03010836 T AT03010836 T AT 03010836T AT 03010836 T AT03010836 T AT 03010836T AT E458006 T1 ATE458006 T1 AT E458006T1
Authority
AT
Austria
Prior art keywords
human monoclonal
lipopolysaccharides
lps
monoclonal antibodies
pseudomonas aeruginosa
Prior art date
Application number
AT03010836T
Other languages
English (en)
Inventor
Alois B Lang
Michael P Horn
Martin A Imboden
Original Assignee
Kenta Biotech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech Ag filed Critical Kenta Biotech Ag
Application granted granted Critical
Publication of ATE458006T1 publication Critical patent/ATE458006T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
AT03010836T 2003-05-14 2003-05-14 Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa ATE458006T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03010836A EP1479695B1 (de) 2003-05-14 2003-05-14 Humaner monoklonaler Antikörper spezifisch für Lipopolysacchariden (LPS) des Serotyps IATS O6 von Pseudomonas aeruginosa

Publications (1)

Publication Number Publication Date
ATE458006T1 true ATE458006T1 (de) 2010-03-15

Family

ID=33040937

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03010836T ATE458006T1 (de) 2003-05-14 2003-05-14 Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa

Country Status (9)

Country Link
US (1) US7597893B2 (de)
EP (1) EP1479695B1 (de)
KR (1) KR100910097B1 (de)
CN (1) CN1788018B (de)
AT (1) ATE458006T1 (de)
CA (1) CA2525657C (de)
DE (1) DE60331292D1 (de)
ES (1) ES2338105T3 (de)
WO (1) WO2004101622A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073631A2 (en) * 2007-11-30 2009-06-11 Kalobios Pharmaceuticals, Inc. Antibodies to the pcrv antigen of pseudomonas aeruginosa
EP2417157A1 (de) * 2009-04-09 2012-02-15 Kenta Biotech AG Für lipopolysaccharide (lps) vom serotyp lats 01 aus pseudomonas aeruginosa spezifischer humaner monoklonaler antikörper
ITFI20090230A1 (it) * 2009-11-04 2011-05-05 Azienda Ospedaliero Universitaria C Areggi Glicoconiugato sintetico immunogeno utile per l'immunoterapia del melanoma.
WO2011102553A1 (en) * 2010-02-18 2011-08-25 Meiji Seika Kaisha, Ltd. Antibody against serotype i lipopolysaccharide of pseudomonas aeruginosa
EP2361989A1 (de) * 2010-02-26 2011-08-31 Kenta Biotech AG Verfahren und Kits zur Serotypisierung von Pseudomonas aeruginosa und Oligonukleotidsequenzen zur Verwendung in solchen Methoden und Kits
CA2826566C (en) 2011-02-08 2022-09-13 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2015002954A1 (en) * 2013-07-03 2015-01-08 Synglyco Pharmaceuticals, Inc. Synthetic oligosaccharides for p. aeruginosa vaccine
EP3374391B1 (de) 2015-11-10 2024-04-17 Visterra, Inc. Antikörpermolekülarzneimittelkonjugate die an lipopolysaccharide binden und verwendungen davon
CN105424929B (zh) * 2015-11-24 2017-08-08 四川夹金山逢春养殖科技有限公司 一种铜绿假单胞菌抗体检测试剂盒及检测方法
CN110431150A (zh) 2017-01-18 2019-11-08 威特拉公司 抗体分子-药物偶联物及其用途
CA3115633A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
JPH04211393A (ja) * 1990-02-08 1992-08-03 Sumitomo Pharmaceut Co Ltd ヒトモノクローナル抗体及びそれを有効成分とする緑膿菌感染症治療剤
WO2002020619A2 (en) * 2000-09-07 2002-03-14 Schreiber John R HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
CA2433800C (en) * 2001-01-05 2016-09-13 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
ES2674888T3 (es) * 2001-06-26 2018-07-04 Amgen Inc. Anticuerpos para OPGL

Also Published As

Publication number Publication date
KR100910097B1 (ko) 2009-07-30
WO2004101622A1 (en) 2004-11-25
DE60331292D1 (de) 2010-04-01
CN1788018A (zh) 2006-06-14
CN1788018B (zh) 2012-04-25
KR20060006967A (ko) 2006-01-20
US7597893B2 (en) 2009-10-06
US20060093610A1 (en) 2006-05-04
EP1479695A1 (de) 2004-11-24
EP1479695B1 (de) 2010-02-17
CA2525657C (en) 2011-11-29
CA2525657A1 (en) 2004-11-25
ES2338105T3 (es) 2010-05-04

Similar Documents

Publication Publication Date Title
IL184774A0 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
BRPI0506771A (pt) anticorpo, e, composição farmacêutica
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
NO20062886L (no) IL-23 og dens reseptor, beslektede reagenser og fremgangsmater
NO20074563L (no) Novel anti-plgf antibody
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
MEP44408A (en) Anti-il-12 antibodies, compositions, methods and uses
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
EA201301072A1 (ru) Антитела против il-23p19 и их применение
UA116614C2 (uk) Антитіло до фактора d і його застосування
CR20120587A (es) Moléculas de unión al antígeno que fijan egfr, vectores que las codifican y uso de las mismas
ME00314B (me) Anti-tnf antitijela, kompozicije, postupci i primjene
WO2006085961A3 (en) Anti-mcp-1 antibodies, compositions, methods and uses
WO2003034903A3 (en) Psma antibodies and protein multimers
HK1118458A1 (en) Anti-il-23 antibodies, compositions, methods and uses
RS53752B1 (en) ANTITELO PROTIV ILT7
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
DK3085783T3 (da) Bispecifikt antistof som substitution for funktionelle proteiner
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
WO2006086208A3 (en) 5-fluoro-uracil immunoassay
WO2006102200A3 (en) Docetaxel immunoassay
ATE458006T1 (de) Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1479695

Country of ref document: EP